Advertisement
Advertisement

ARQT

ARQT logo

Arcutis Biotherapeutics, Inc. Common Stock

28.26
USD
Sponsored
+0.73
+2.65%
Jul 21, 16:00 UTC -4
Closed
exchange

After-Market

28.42

+0.16
+0.57%

ARQT Earnings Reports

Positive Surprise Ratio

ARQT beat 21 of 26 last estimates.

81%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$121.23M
/
$0.03
Implied change from Q1 26 (Revenue/ EPS)
+15.02%
/
-133.33%
Implied change from Q2 25 (Revenue/ EPS)
+48.74%
/
-123.08%

Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue

On May 06, 2026, ARQT reported earnings of -0.09 USD per share (EPS) for Q1 26, missing the estimate of -0.08 USD, resulting in a -7.40% surprise. Revenue reached 105.40 million, compared to an expected 103.29 million, with a 2.04% difference. The market reacted with a -14.52% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 121.23 million USD, implying an decrease of -133.33% EPS, and increase of 15.02% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jul 09, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.81
Surprise
-10.78%
logo
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
logo
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
For Q1 2026, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of -$0.09, missing estimates by -7.4%, and revenue of $105.40M, 2.04% above expectations.
The stock price moved down -14.52%, changed from $24.17 before the earnings release to $20.66 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 6 analysts, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of $0.03 and revenue of $121.23M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement